XTalks

JANUARY 5, 2021

Both drug discovery and drug repurposing to manage and treat the disease will also continue as experts learn more about the virology and epidemiology of the novel SARS-CoV-2 coronavirus that wreaked havoc in 2020. These include monoclonal antibody drugs, which are attractive therapeutic agents owing to their targeted specificity.

Life Science 98

Life Science Clinical Trials Clinical Trials Trials 98

XTalks

DECEMBER 17, 2021

Xtalks is taking a look at some of the major stories and innovations of the year in the life sciences, many of which were driven by new, emerging and improved technologies. The year 2021 was all about continuing innovations in the life sciences. Life Science Innovations: Malaria and Influenza Vaccines.

Life Science 98

Life Science Vaccine Vaccination Trials 98

XTalks

JUNE 23, 2022

The drug has become the first approved systemic treatment for the autoimmune disorder that causes patchy hair loss. Ayesha also discussed the FDA approval of Alnylam’s RNAi therapeutic Amvuttra for the treatment of polyneuropathy associated with a rare protein disorder called hereditary transthyretin-mediated (ATTR) amyloidosis.

Life Science 52

Life Science FDA Approval Protein Drugs 52

BioPharma Reporter

MARCH 22, 2022

Fujifilm Irvine Scientific, Inc, has announced the acquisition of Shenandoah Biotechnology, a company supplying recombinant proteins to the drug discovery, life science research, and cell and gene therapy markets.

Gene Therapy 98

Gene Therapy Life Science Protein Gene 98

XTalks

MARCH 31, 2023

By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability. This can help guide better drug formulations, delivery of higher therapeutic doses and improved biomanufacturing processes.

Protein 97

Protein Research Development Manufacturing 97

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. At the helm of this venture is Dr. Taylor H. How is your lead program differentiated?

Protein 94

Protein Development Clinical Trials Clinical Trials 94

XTalks

NOVEMBER 26, 2024

The US Food and Drug Administration (FDA) has approved Attruby (acoramidis) , marking a significant advancement for patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). This progressive disease occurs when misfolded transthyretin (TTR) proteins form amyloid deposits in the heart, leading to cardiac dysfunction.

Genetic Disease 105

Genetic Disease Genetics Protein Clinical Development 105

pharmaphorum

JULY 26, 2021

The most complete database of protein structures ever assembled, developed with the help of Google’s artificial intelligence unit DeepMind, has been made freely available to researchers around the world. Around a third of the structures are considered to be detailed and precise enough to allow drug design.

Protein 130

Protein Genome Genomics Life Science 130

XTalks

FEBRUARY 19, 2025

Deciphera leverages its proprietary switch-control kinase inhibitor platform targeting kinase activation to develop orally administered drug candidates, reflecting its commitment to innovative treatments for conditions with limited therapeutic options. In 2024, Deciphera was acquired by ONO Pharmaceutical for $2.4

FDA Approval 59

FDA Approval Drugs Trials Clinical Trials 59

XTalks

JULY 20, 2022

It is also the first protein-based COVID-19 vaccine to be authorized in the country. Ayesha also talked about the expanded label approval of Horizon Therapeutics’ gout medication Krystexxa to include its co-administration with arthritis and chemotherapy drug methotrexate. Krystexxa Chronic Gout Medication Gets Expanded FDA Approval.

Life Science 52

Life Science Vaccine Vaccination Drugs 52

XTalks

JANUARY 21, 2025

The FDA has approved Datroway (datopotamab deruxtecan-dlnk), a TROP2-directed antibody-drug conjugate (ADC) for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer, developed through a global collaboration between Daiichi Sankyo and AstraZeneca. Datroway leverages DXd technology to precisely target cancer cells.

Antibody 105

Antibody FDA Approval HR Trials 105

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 1.351 variant.

Protein 97

Protein Vaccine Vaccination Trials 97

pharmaphorum

JANUARY 11, 2023

A slow journey to drug discovery. Asked about the impetus behind Verseon’s work in the sector, Prakash explained that he began the company “to change the way the world finds new drugs”. Today’s pharmaceutical drug discovery process essentially relies on trial and error,” he expanded. “To Not an unambitious goal.

Big Data 122

Big Data Drugs Clinical Trials Clinical Trials 122

Pharmaceutical Technology

FEBRUARY 13, 2023

Although recently approved drugs can treat seizures more safely, they do not treat the comorbidities that patients experience. Rather than replacing mutated genes with functional copies, STK-001 promotes protein production in the healthy copy of the SCN1a gene. Some newly approved drugs have improved the situation.

Research 264

Research Gene Gene Therapy Genome 264

XTalks

JANUARY 7, 2025

In a major leap forward for trauma care, Humacyte has received full approval from the US Food and Drug Administration (FDA) for Symvess, a first-of-its-kind bioengineered human tissue designed to repair extremity arterial injuries. When an artery is damaged, restoring blood flow quickly is crucial.

FDA Approval 105

FDA Approval Engineer Clinical Trials Clinical Trials 105

XTalks

MAY 29, 2024

Cocrystal Pharma leverages a unique structure-based drug discovery platform, complemented by Nobel Prize-winning expertise, to develop leading-edge antiviral drugs that are both first-in-class and best-in-class. Dr. Lee brings over 25 years of experience in anti-infective drug discovery research to his role.

Life Science 52

Life Science FDA Approval Drugs Development 52

XTalks

DECEMBER 26, 2024

The BROADWAY trial tested obicetrapib, a novel cholesteryl ester transfer protein (CETP) inhibitor, as a monotherapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Unlike CETP inhibitors, PCSK9 inhibitors block a protein that regulates cholesterol levels.

Trials 52

Trials Life Science Clinical Trials Clinical Trials 52

XTalks

OCTOBER 24, 2024

Meanwhile, Innovent Biologics recently saw its New Drug Application (NDA) for picankibart, an IL-23p19 inhibitor, accepted by the Chinese National Medical Products Administration (NMPA). This drug may significantly improve psoriasis care by offering effective long-term control with fewer side effects.

Research 105

Research Dermatology Clinical Trials Clinical Trials 105

XTalks

JUNE 20, 2022

Alnylam Pharmaceuticals, a leading RNA interference (RNAi) therapeutics biopharmaceutical company, announced it received approval from the US Food and Drug Administration (FDA) for its RNAi therapeutic Amvuttra (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (ATTR) amyloidosis in adults.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

XTalks

OCTOBER 22, 2024

Astellas Pharma has won approval from the US Food and Drug Administration (FDA) for Vyloy (zolbetuximab) as a first-line treatment for adults with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The drug is specifically indicated for patients whose tumors are HER2-negative and express claudin 18.2 months from 15.5

FDA Approval 105

FDA Approval Drugs Licensing Licensing 105

XTalks

OCTOBER 16, 2024

Sam Lee, Co-Chief Executive Officer and President of Cocrystal Pharma, a clinical-stage biotech company focusing on antiviral drug development with a unique structure-based drug discovery platform. As the conversation wraps up, Dr. Lee discusses his excitement for the future of antiviral drug development.

Development 64

Development Drugs Life Science Protein 64

Pharmaceutical Technology

JUNE 4, 2023

There are two main genes in the AAV genome, rep and cap, which encode nine different proteins. Transcription of the rep gene is initiated from the p5 or p19 promoters to, respectively, produce the large (Rep78 and Rep68) and small (Rep52 and Rep40) nonstructural Rep proteins.

Gene 262

Gene Gene Therapy Genetics DNA 262

XTalks

NOVEMBER 23, 2021

The reliance of COVID-19 vaccine manufacturing on only a handful of countries globally has made many nations realize the need for large-scale, domestic biomanufacturing facilities for drugs and vaccines as preparation for potential disease outbreaks and health emergencies in the future.

Manufacturing 98

Manufacturing Vaccine Vaccination Drugs 98

pharmaphorum

NOVEMBER 6, 2022

In 2021, five out of the top 10 selling drugs were mAbs and this trend is forecasted to remain the same over the next five years. Artificial Intelligence (AI) and deep learning have already transformed several aspects of small molecule drug design. The potential of monoclonal antibodies (mAbs) as therapies is indisputable.

Antibody 123

Antibody Drugs Protein Life Science 123

XTalks

NOVEMBER 8, 2024

Top Hospital-Based Healthcare Innovations Google DeepMind AlphaFold 3: Rendering Molecules in HD Drug discovery often hinges on predicting how proteins interact with each other. Understanding these interactions is like solving a three-dimensional puzzle with thousands of pieces.

Doctor 104

Doctor Doctors Protein Nurses 104

XTalks

MARCH 11, 2025

Vepdegestrant, an investigational oral therapy, utilizes PROteolysis TArgeting Chimera (PROTAC) technology a mechanism that harnesses the bodys natural protein disposal system to selectively target and degrade the estrogen receptor. From a business perspective, Arvinas fourth quarter financial highlights report that revenue surged to $263.4

Trials 59

Trials Clinical Trials Clinical Trials Protein 59

XTalks

AUGUST 17, 2020

Viltepso (viltolarsen), an injectable drug developed by NS Pharma, has gone through the US Food and Drug Administration’s (FDA) accelerated approval process, but the company has yet to confirm that the drug has a true clinical benefit.

Drugs 105

Drugs Clinical Trials Clinical Trials Gene 105

XTalks

NOVEMBER 21, 2024

The US Food and Drug Administration (FDA) has granted Breakthrough Device clearance to Ultromics’ EchoGo Amyloidosis device through its Total Product Lifecycle Advisory Program (TAP). Cardiac amyloidosis, a serious and often underdiagnosed heart condition, poses significant diagnostic challenges even for experienced clinicians.

Production 105

Production Protein Life Science Trials 105

Delveinsight

JULY 29, 2021

Biogen-Ionis’ experimental drug meets primary goal in Alzheimer’s trial. Biogen and Ionis Pharmaceuticals have demonstrated that their experimental drug, BIIB080 (IONIS-MAPT), fulfilled the primary goal of safety and tolerability in the Phase Ib multiple ascending doses (MAD) clinical trials in mild Alzheimer’s disease patients.

Drugs 98

Drugs Protein Life Science Development 98

XTalks

MAY 24, 2022

Antiretroviral drugs for HIV are classified as integrase strand transfer inhibitors (INSTIs), nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), cytochrome P4503A (CYP3A) inhibitors, protease inhibitors (PIs) and others. Lenacapavir: A Treatment Candidate for HIV.

Drugs 98

Drugs Clinical Trials Clinical Trials Trials 98

XTalks

JULY 28, 2020

Excipients can take many forms, such as bulking agents, binders, coatings and colourants, and they are chosen based on their ability to aid in drug delivery, administration and even in pill identification and prevention of counterfeiting.

Protein 103

Protein Drugs In-Vitro Scientist 103

XTalks

FEBRUARY 26, 2024

The US Food and Drug Administration (FDA) has granted expanded approval to Genentech’s (part of Roche) Xolair (omalizumab) to help reduce allergic reactions to various foods after accidental exposure. This amount is equivalent to about two and a half peanuts or half a teaspoon of regular peanut butter.

Allergies 100

Allergies FDA Approval Drugs Protein 100

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nedisertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nedisertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MAY 8, 2023

This protein also serves as a target for neutralizing antibodies, which can be used to develop for therapeutic as well as diagnostic applications. There are four types of influenza viruses: A, B, C, and D. Hemagglutinin (HA), an envelope glycoprotein on the influenza virion enables the virus to enter and spread between cells.

Antibody 246

Antibody Vaccination Vaccine Dermatology 246

XTalks

JULY 20, 2022

The production facility will be equipped to develop and manufacture plasmid DNA, nucleic acids, recombinant proteins and other therapeutics produced through methods involving microbial fermentation. Related: Biovectra to Build First mRNA Vaccine and Drug Manufacturing Plant in Canada. In addition to a $39.8

Vaccine 105

Vaccine Vaccination Manufacturing Life Science 105

XTalks

MARCH 18, 2025

By inhibiting this protein, povorcitinib reduces the inflammatory signals that contribute to abscess and nodule formation. As reported by Investors.com , RBC Capital Markets analyst Brian Abrahams stated, The drug did hit on statistical significance and could be a viable entrant.

Trials 59

Trials Clinical Trials Clinical Trials Hormones 59